Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) saw strong trading volume on Thursday . 546,091 shares were traded during trading, a decline of 18% from the previous session’s volume of 662,731 shares.The stock last traded at $3.29 and had previously closed at $3.41.

A number of equities analysts have commented on the stock. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Tuesday, April 26th. Jefferies Group reaffirmed a “buy” rating on shares of Anthera Pharmaceuticals in a research note on Thursday, June 9th. HC Wainwright assumed coverage on shares of Anthera Pharmaceuticals in a research note on Friday, July 8th. They set a “buy” rating and a $10.00 target price on the stock. Finally, FBR & Co reaffirmed a “hold” rating on shares of Anthera Pharmaceuticals in a research note on Monday, June 20th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $9.58.

The company’s market capitalization is $131.57 million. The firm’s 50 day moving average price is $3.37 and its 200 day moving average price is $3.50.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.01. On average, equities analysts anticipate that Anthera Pharmaceuticals Inc. will post ($1.26) EPS for the current year.

Anthera Pharmaceuticals Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company’s primary Phase 3 product candidate blisibimod targets elevated levels of Bcell activating factor (BAFF) which has been associated with a variety of Bcell mediated autoimmune diseases including systemic lupus erythematosus or lupus IgA nephropathy lupus nephritis multiple myeloma and others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.